Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

27 de diciembre de 2019 actualizado por: GlaxoSmithKline

Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants

This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2 months at the time of the first dose and previously uninfected with HRV. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Descripción general del estudio

Descripción detallada

Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV) vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo.

Tipo de estudio

Intervencionista

Inscripción (Actual)

765

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Aichi, Japón, 451-0052
        • GSK Investigational Site
      • Chiba, Japón, 275-8580
        • GSK Investigational Site
      • Fukuoka, Japón, 802-8533
        • GSK Investigational Site
      • Hiroshima, Japón, 720-8520
        • GSK Investigational Site
      • Hiroshima, Japón, 734-8530
        • GSK Investigational Site
      • Hiroshima, Japón, 737-0811
        • GSK Investigational Site
      • Hiroshima, Japón, 730-8518
        • GSK Investigational Site
      • Hiroshima, Japón, 730-8798
        • GSK Investigational Site
      • Hokkaido, Japón, 065-0033
        • GSK Investigational Site
      • Hokkaido, Japón, 003-0021
        • GSK Investigational Site
      • Kagawa, Japón, 765-8501
        • GSK Investigational Site
      • Kanagawa, Japón, 247-8533
        • GSK Investigational Site
      • Miyagi, Japón, 983-8520
        • GSK Investigational Site
      • Miyagi, Japón, 981-3203
        • GSK Investigational Site
      • Nagano, Japón, 386-8610
        • GSK Investigational Site
      • Nagasaki, Japón, 856-8562
        • GSK Investigational Site
      • Niigata, Japón, 957-8588
        • GSK Investigational Site
      • Okayama, Japón, 701-1192
        • GSK Investigational Site
      • Okayama, Japón, 701-0204
        • GSK Investigational Site
      • Osaka, Japón, 591-8025
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 mes a 3 meses (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Born between a gestation period of 36 and 42 weeks inclusive.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.
  • History of use of experimental rotavirus vaccine.
  • Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.
  • Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Previous confirmed occurrence of RV GE.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
  • A family history of congenital or hereditary immunodeficiency.
  • Acute disease at the time of enrolment.
  • Gastroenteritis within 7 days preceding the study vaccine administration.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Rotarix Group
Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
Two-dose oral vaccination.
Comparador de placebos: Placebo Group
Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
Two-dose oral administration.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Periodo de tiempo: From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Periodo de tiempo: From 2 weeks after Dose 2 up to 2 years of age
A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type
Periodo de tiempo: From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types
Periodo de tiempo: From 2 weeks after Dose 2 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains
Periodo de tiempo: From 2 weeks after Dose 2 up to 2 years of age
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
From 2 weeks after Dose 2 up to 2 years of age
Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
Periodo de tiempo: From Dose 1 up to 2 years of age

Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.

Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).

From Dose 1 up to 2 years of age
Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration
Periodo de tiempo: 2 months after Dose 2
Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).
2 months after Dose 2
Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies
Periodo de tiempo: 2 months after Dose 2
Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.
2 months after Dose 2
Number of Subjects Reporting Solicited Symptoms
Periodo de tiempo: During the 8-day follow-up period after each dose
Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.
During the 8-day follow-up period after each dose
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Periodo de tiempo: During the 31-day follow-up period after each dose
Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
During the 31-day follow-up period after each dose
Number of Subjects Reporting Serious Adverse Events (SAEs)
Periodo de tiempo: Up to 2 years of age
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Up to 2 years of age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de junio de 2007

Finalización primaria (Actual)

31 de marzo de 2009

Finalización del estudio (Actual)

21 de noviembre de 2009

Fechas de registro del estudio

Enviado por primera vez

29 de mayo de 2007

Primero enviado que cumplió con los criterios de control de calidad

29 de mayo de 2007

Publicado por primera vez (Estimar)

30 de mayo de 2007

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de enero de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

27 de diciembre de 2019

Última verificación

1 de diciembre de 2019

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 107625
  • 2015-001543-36 (Número EudraCT)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

IPD is available via the Clinical Study Data Request site (click on the link provided below)

Marco de tiempo para compartir IPD

IPD is available via the Clinical Study Data Request site (click on the link provided below)

Criterios de acceso compartido de IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Datos del estudio/Documentos

  1. Formulario de consentimiento informado
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  2. Plan de Análisis Estadístico
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  3. Conjunto de datos de participantes individuales
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  4. Protocolo de estudio
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  5. Especificación del conjunto de datos
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  6. Formulario de informe de caso anotado
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  7. Informe de estudio clínico
    Identificador de información: 107625
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir